Hemay007 vs infliximab-dyyb (Zymfentra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

Hemay007

Developed by Tianjin Hemay Pharmaceutical

Phase 1 in Crohn's Diseasesmall molecule
Weak signal

NCT02603185 · Phase 1 · status unknown

This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03945019 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHemay007infliximab-dyyb (Zymfentra)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

Hemay007
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (induction)

Hemay007
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

Hemay007
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (maintenance)

Hemay007
—Not reported
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hemay007: no structured comparison results are available for Crohn's Disease.

infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay007's landscape · infliximab-dyyb (Zymfentra)'s landscape